V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10458735 | 10043180 | 1.53 | 96 | Adjuvant (A) | 2019-11-28 | 2019-12-03 | EC | N | N | CHLORAMBUCIL + OFATUMUMAB | 101831925 |
| 10462720 | 10043188 | 1.7 | 53.2 | Palliative (P) | 2019-09-11 | 2019-09-17 | Fulvestrant + Palbociclib | 02 | null | ANAGRELIDE | 100918872 |
| 10464834 | 10043192 | 1.56 | 75 | null | 2021-11-15 | 2021-12-03 | FLAG + Idarubicin | N | N | FURVA TRIAL | 100372596 |
| 10465770 | 10043195 | null | 74 | 03 | null | 2019-03-05 | CISPLATIN + RT | null | N | STAMPEDE TRIAL | 100092830 |
| 10467063 | 10043199 | 1.65 | 75 | 03 | 2019-01-28 | 2019-01-30 | Bexarotene | 02 | N | DOXORUBICIN + OLARATUMAB | 101032305 |
| 10467459 | 10043201 | 1.85 | 0 | Neo-adjuvant (N) | 2020-09-18 | 2020-09-19 | ECX | 02 | N | CISPLATIN + RT | 100466048 |
| 10471153 | 10043206 | 0 | 0 | Curative (C) | 2020-09-22 | 2020-09-27 | ECX | 02 | N | OSIMERTINIB | 101330513 |
| 10475499 | 10043212 | 1.75 | 75.5 | Neo-adjuvant (N) | 2018-09-12 | 2018-09-12 | GEMCITABINE + PACLITAXEL ALBUMIN (ABRAXANE) | 02 | N | IDELALISIB + RITUXIMAB | 101779506 |
| 10477519 | 10043214 | null | 0 | 03 | 2019-06-11 | 2019-06-25 | Cetuximab + FOLFIRI cycle 2 onwards | N | null | BLEOMYCIN + DACARBAZINE + DOXORUBICIN + VINBLASTINE | 100200915 |
| 10479899 | 10043218 | 1.6 | 65.5 | Palliative (P) | 2018-10-19 | 2018-10-31 | Cytarabine High Dose | 02 | N | BORTEZOMIB + DARATUMUMAB | 101715823 |
| 10480687 | 10043219 | 1.6 | 91.6 | Palliative (P) | 2019-06-25 | 2019-07-10 | MELPHALAN + THALIDOMIDE | 02 | N | IDELALISIB | 101792844 |
| 10480742 | 10043220 | 1.68 | 71 | Curative (C) | null | 2019-12-12 | Everolimus 10mg | null | N | MYELOMA XI TRIAL | 101861899 |
| 10136138 | 10043223 | 1.72 | 59.4 | Palliative (P) | 2017-05-09 | 2017-05-10 | Bendamustine + prednisolone | 02 | N | CETUXIMAB + IRINOTECAN + MDG | 101813023 |
| 10140286 | 10043224 | 0 | 91 | null | 2022-03-26 | 2022-03-26 | VINCRISTINE | 02 | null | ELOQUENT2 TRIAL | 101061635 |
| 10161782 | 10043225 | null | 87 | null | 2019-04-16 | 2019-04-16 | FLAG + Idarubicin | 02 | null | AZACITIDINE + VENETOCLAX | 101686103 |
| 10219474 | 10043228 | null | null | Palliative (P) | 2019-08-14 | 2019-08-14 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | N | LOMUSTINE | 100206261 |
| 10231904 | 10043231 | 1.63 | 101.7 | Palliative (P) | 2020-01-08 | 2020-01-09 | Obinutuzumab + Venetoclax | 02 | null | FEC | 101636948 |
| 10235674 | 10043232 | 0 | 47.5 | null | 2017-10-21 | 2017-11-12 | null | 02 | null | ATEZOLIZUMAB + CARBOPLATIN + ETOPOSIDE | 101861152 |
| 10293097 | 10043242 | 1.69 | 63.5 | 03 | 2019-01-09 | 2019-01-09 | Radium 223 | 02 | N | CARBOPLATIN + PACLITAXEL + PEMBROLIZUMAB | 100052121 |
| 10298326 | 10043244 | 1.57 | 77 | Palliative (P) | 2020-01-17 | 2020-01-30 | Niraparib | 02 | N | CARBOPLATIN + DOCETAXEL | 100541130 |
| 10299466 | 10043246 | 1.69 | 49.9 | null | 2022-05-08 | 2022-05-15 | Bortezomib + Daratumumab | 02 | null | PARTNER TRIAL | 101121422 |
| 10304540 | 10043247 | 1.73 | null | Neo-adjuvant (N) | 2020-03-25 | 2020-04-24 | null | 02 | N | IDELALISIB + RITUXIMAB | 101609384 |
| 10330421 | 10043250 | null | 73.5 | null | 2021-07-19 | 2021-07-19 | DOCETAXEL + GEMCITABINE | 02 | null | CISPLATIN + RT | 100171223 |
| 10331943 | 10043252 | 1.75 | 59.4 | Neo-adjuvant (N) | 2019-12-22 | 2020-02-12 | null | null | null | TIVOZANIB | 100062157 |
| 10347062 | 10043254 | 1.8 | 63.2 | null | 2022-02-16 | 2022-02-16 | Busulfan Oral | 02 | null | IRINOTECAN + MDG | 101330473 |
| 10349659 | 10043257 | 1.85 | 73.2 | Neo-adjuvant (N) | 2019-04-29 | 2019-04-29 | Brentuximab Vedotin + Cyclophosphamide + Doxorubicin | 02 | N | CISPLATIN + METHOTREXATE + VINBLASTINE | 100533354 |
| 10410151 | 10043263 | 1.71 | 92.55 | Palliative (P) | 2019-10-24 | 2019-10-24 | Bortezomib + Panobinostat | 02 | Y | BENDAMUSTINE + POLATUZUMAB VEDOTIN + RITUXIMAB | 100800127 |
| 10415238 | 10043265 | 1.8 | 98 | null | 2017-11-11 | 2017-11-17 | null | 02 | null | ATEZOLIZUMAB + CARBOPLATIN + ETOPOSIDE | 100803491 |
| 10457743 | 10043271 | 1.82 | 72.1 | 03 | 2021-09-18 | 2021-09-28 | Bortezomib + Panobinostat | 02 | N | BINIMETINIB + ENCORAFENIB | 100085056 |
| 10406436 | 10051958 | 1.68 | null | null | 2020-04-19 | 2020-05-10 | IBRUTINIB | null | null | IBRUTINIB | 101622655 |
| 10406450 | 10051960 | 1.8 | 110 | null | 2013-08-20 | 2013-09-11 | IBRUTINIB | null | null | IBRUTINIB | 100599735 |
| 10406513 | 10051961 | null | 101.3 | null | 2019-12-25 | 2021-01-27 | IBRUTINIB | 02 | null | IBRUTINIB | 101480885 |
| 10406516 | 10051962 | 1.7 | 70 | null | null | 2015-09-13 | Rituximab (Maintenance) | null | null | RITUXIMAB | 100864473 |
| 10406525 | 10051963 | 1.8 | 72.3 | null | 2019-05-27 | 2019-06-01 | IBRUTINIB | null | null | IBRUTINIB | 101482756 |
| 10406578 | 10051964 | 1.67 | 62 | null | 2017-03-30 | 2017-09-19 | IBRUTINIB | null | null | IBRUTINIB | 100003417 |
| 10406599 | 10051965 | 1.79 | 77.2 | null | 2021-01-21 | 2021-01-27 | Rituximab | 02 | null | RITUXIMAB | 100282062 |
| 10406683 | 10051966 | 1.73 | 63 | null | 2019-04-19 | 2019-09-10 | IBRUTINIB | null | null | RITUXIMAB | 100670318 |
| 10406691 | 10051967 | 1.73 | null | null | 2016-11-29 | 2017-11-17 | Rituximab | null | null | RITUXIMAB | 100595290 |
| 10406701 | 10051968 | 1.68 | null | null | 2017-03-17 | 2017-04-04 | IBRUTINIB | null | null | RITUXIMAB | 100216225 |
| 10406729 | 10051969 | 1.54 | 68.2 | null | 2020-01-11 | 2020-01-11 | IBRUTINIB | null | null | RITUXIMAB | 101736437 |
| 10406759 | 10051970 | null | 75.6 | null | 2021-09-17 | 2021-09-17 | IBRUTINIB | null | null | RITUXIMAB | 100393538 |
| 10406763 | 10051971 | null | 86.7 | null | null | 2017-09-07 | Rituximab | null | null | RITUXIMAB | 100114913 |
| 10406799 | 10051973 | 1.72 | 65.7 | null | 2021-03-17 | 2021-03-20 | IBRUTINIB | null | null | IBRUTINIB | 101445494 |
| 10406811 | 10051974 | 1.66 | 78 | null | 2016-06-17 | 2016-07-03 | Rituximab | 02 | N | RITUXIMAB | 101824931 |
| 10406850 | 10051975 | 0 | 67.7 | null | null | 2016-03-22 | IBRUTINIB | 02 | null | RITUXIMAB | 100143231 |
| 10406854 | 10051976 | 1.74 | 86.2 | null | null | 2018-11-14 | IBRUTINIB | null | null | RITUXIMAB | 100726850 |
| 10406889 | 10051978 | 1.83 | 54.7 | Palliative (P) | 2016-12-14 | 2019-09-07 | IBRUTINIB | null | N | IBRUTINIB | 101284721 |
| 10406906 | 10051979 | 1.69 | 57 | null | 2022-04-27 | 2022-05-04 | IBRUTINIB | null | null | IBRUTINIB | 100373690 |
| 10406995 | 10051981 | null | 83.8 | null | null | 2021-08-04 | Rituximab | null | null | RITUXIMAB | 100721233 |
| 10407081 | 10051985 | 1.77 | 90 | null | null | 2019-12-25 | IBRUTINIB | null | null | RITUXIMAB | 101183111 |